UroGen Pharma Ltd. Stock Split Ratio
UroGen Pharma Ltd. (URGN) had Stock Split Ratio of 320.00% as of 2017-04-19, per its 6-K filed 2018-11-13.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2018-11-13
- 2017-04-19: Stockholders' Equity Note, Stock Split, Conversion Ratio 320.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2017-04-19 | 320.00% 6-K · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |